Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$46.85−0.77 (-1.62%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Enliven Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Enliven Therapeutics's enterprise value was $2.85B on Nov 11, 2026, against $802.44M a year earlier. Over the last 5 years it ranged from -$85.27M to $3.35B, with a median of $581.82M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.85B | +556.2% |
| 2025 | Dec 31, 2025 | $435.02M | -43.6% |
| 2024 | Dec 31, 2024 | $771.42M | +151.5% |
| 2023 | Dec 29, 2023 | $306.78M | – |
| 2022 | Dec 30, 2022 | -$4.69M | – |
| 2021 | Dec 31, 2021 | -$74.42M | -184.7% |
| 2020 | Dec 31, 2020 | $87.82M | – |
See a number that looks wrong?